NOVAVAX INC(NASDAQ:NVAX) stock Fundamental Analysis

Fundamental Rating

NVAX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. NVAX has a medium profitability rating, but doesn't score so well on its financial health evaluation. NVAX is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NVAX was profitable.

NVAX had a negative operating cash flow in the past year.

NVAX had negative earnings in each of the past 5 years.

In the past 5 years NVAX reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of NVAX (37.02%) is better than 99.29% of its industry peers.

With an excellent Return On Invested Capital value of 38.36%, NVAX belongs to the best of the industry, outperforming 99.64% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	37.02%
ROE	N/A
ROIC	38.36%

ROA(3y)-23.82%

ROA(5y)-33.12%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NVAX's Profit Margin of 38.14% is amongst the best of the industry. NVAX outperforms 98.40% of its industry peers.

The Operating Margin of NVAX (33.69%) is better than 98.57% of its industry peers.

NVAX has a Gross Margin of 87.52%. This is amongst the best in the industry. NVAX outperforms 89.84% of its industry peers.

		Industry Rank	Sector Rank
OM	33.69%
PM (TTM)	38.14%
GM	87.52%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NVAX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.

NVAX has more shares outstanding than it did 1 year ago.

NVAX has more shares outstanding than it did 5 years ago.

The debt/assets ratio for NVAX is higher compared to a year ago.

2.2 Solvency

NVAX has an Altman-Z score of -1.89. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.

NVAX's Altman-Z score of -1.89 is in line compared to the rest of the industry. NVAX outperforms 55.79% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-1.89

ROIC/WACC3.79

WACC10.11%

2.3 Liquidity

A Current Ratio of 2.06 indicates that NVAX has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 2.06, NVAX is doing worse than 74.51% of the companies in the same industry.

NVAX has a Quick Ratio of 2.03. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.

NVAX's Quick ratio of 2.03 is on the low side compared to the rest of the industry. NVAX is outperformed by 72.91% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.06
Quick Ratio	2.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 173.50%, which is quite impressive.

NVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.92%.

NVAX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.31% yearly.

EPS 1Y (TTM)173.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%379.05%

Revenue 1Y (TTM)25.92%

Revenue growth 3Y-15.89%

Revenue growth 5Y105.31%

Sales Q2Q%610.3%

3.2 Future

The Earnings Per Share is expected to grow by 19.82% on average over the next years. This is quite good.

The Revenue is expected to decrease by -8.27% on average over the next years.

EPS Next Y251.87%

EPS Next 2Y49.43%

EPS Next 3Y21.86%

EPS Next 5Y19.82%

Revenue Next Year36.71%

Revenue Next 2Y-12.41%

Revenue Next 3Y-26.24%

Revenue Next 5Y-8.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 3.13 indicates a rather cheap valuation of NVAX.

Compared to the rest of the industry, the Price/Earnings ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 99.29% of the companies listed in the same industry.

NVAX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.91.

A Price/Forward Earnings ratio of 18.97 indicates a rather expensive valuation of NVAX.

NVAX's Price/Forward Earnings ratio is rather cheap when compared to the industry. NVAX is cheaper than 92.51% of the companies in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 21.85. NVAX is around the same levels.

		Industry Rank	Sector Rank
PE	3.13
Fwd PE	18.97

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NVAX is valued cheaply inside the industry as 99.47% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	0.39

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as NVAX's earnings are expected to grow with 21.86% in the coming years.

PEG (NY)0.01

PEG (5Y)N/A

EPS Next 2Y49.43%

EPS Next 3Y21.86%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NVAX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVAVAX INC

NASDAQ:NVAX (5/22/2025, 8:00:01 PM)

After market: 7.2969 +0.01 (+0.09%)

7.29

+0.18 (+2.53%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)08-06 2025-08-06

Inst Owners60.5%

Inst Owner Change-3.77%

Ins Owners0.35%

Ins Owner Change22.03%

Market Cap1.18B

Analysts78.46

Price Target17 (133.2%)

Short Float %28.64%

Short Ratio6.45

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)124.28%

Min EPS beat(2)-58.31%

Max EPS beat(2)306.88%

EPS beat(4)2

Avg EPS beat(4)53.44%

Min EPS beat(4)-58.31%

Max EPS beat(4)306.88%

EPS beat(8)5

Avg EPS beat(8)21.96%

EPS beat(12)6

Avg EPS beat(12)-34.55%

EPS beat(16)6

Avg EPS beat(16)-60.38%

Revenue beat(2)2

Avg Revenue beat(2)46.34%

Min Revenue beat(2)2.61%

Max Revenue beat(2)90.08%

Revenue beat(4)3

Avg Revenue beat(4)23.46%

Min Revenue beat(4)-11.17%

Max Revenue beat(4)90.08%

Revenue beat(8)5

Avg Revenue beat(8)20.39%

Revenue beat(12)6

Avg Revenue beat(12)7.16%

Revenue beat(16)6

Avg Revenue beat(16)-2.44%

PT rev (1m)-5.66%

PT rev (3m)-4.21%

EPS NQ rev (1m)-123.23%

EPS NQ rev (3m)-107.08%

EPS NY rev (1m)216.99%

EPS NY rev (3m)1159.83%

Revenue NQ rev (1m)-4.95%

Revenue NQ rev (3m)-30.59%

Revenue NY rev (1m)38.53%

Revenue NY rev (3m)68.02%

Valuation

		Industry Rank	Sector Rank
PE	3.13
Fwd PE	18.97
P/S	0.94
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	0.39

EPS(TTM)2.33

EY31.96%

EPS(NY)0.38

Fwd EY5.27%

FCF(TTM)-1.21

FCFYN/A

OCF(TTM)-1.17

OCFYN/A

SpS7.75

BVpS-0.47

TBVpS-1.16

PEG (NY)0.01

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	37.02%
ROE	N/A
ROCE	48.55%
ROIC	38.36%
ROICexc	239.72%
ROICexgc	1222.82%
OM	33.69%
PM (TTM)	38.14%
GM	87.52%
FCFM	N/A

ROA(3y)-23.82%

ROA(5y)-33.12%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.97

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	0.48
Cap/Depr	16.56%
Cap/Sales	0.59%
Interest Coverage	22.06
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.06
Quick Ratio	2.03
Altman-Z	-1.89

F-Score5

WACC10.11%

ROIC/WACC3.79

Cap/Depr(3y)158.98%

Cap/Depr(5y)408.8%

Cap/Sales(3y)4.02%

Cap/Sales(5y)5.71%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)173.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%379.05%

EPS Next Y251.87%

EPS Next 2Y49.43%

EPS Next 3Y21.86%

EPS Next 5Y19.82%

Revenue 1Y (TTM)25.92%

Revenue growth 3Y-15.89%

Revenue growth 5Y105.31%

Sales Q2Q%610.3%

Revenue Next Year36.71%

Revenue Next 2Y-12.41%

Revenue Next 3Y-26.24%

Revenue Next 5Y-8.27%

EBIT growth 1Y211.83%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year94.57%

EBIT Next 3Y13.97%

EBIT Next 5YN/A

FCF growth 1Y73.75%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y71.02%

OCF growth 3YN/A

OCF growth 5YN/A

NOVAVAX INC (NVAX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens